Abstract
To compare midterm outcomes of patients who were treated with the Nellix device for endovascular aneurysm sealing (EVAS) within the revised instructions for use (rIFU) to those who were treated outside the rIFU.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
